ArticleEndocrine2026
Management of Graves' Disease in Chinese Children and adolescents: A survey of current clinical practice.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the current status of treatment, monitoring strategies, and variations in clinical decision-making for childhood Graves' disease (GD) among Chinese children.
methodsA self-designed questionnaire was distributed via an online platform to physicians from the Endocrine Genetic Metabolism Group of the Pediatric Branch of the Chinese Medical Association and the Western Pediatric Endocrine Genetic Metabolism Cooperative Group. The survey covered the acceptance of recommended initial methimazole (MMI) doses, as well as actual practices regarding initial dose selection, dosing frequency, monitoring parameters and frequency, and criteria for drug discontinuation.
resultsA total of 276 valid questionnaires were collected; 99.3% preferred MMI as first-line treatment. Physicians were stratified into high-volume (> 20 cases, n = 70) and low-volume (≤ 20 cases, n = 206) groups based on the number of new GD cases treated per year. The high-volume group more frequently believed drug instructions and guideline-recommended initial doses required adjustment and selected higher initial doses (> 0.3-0.5 mg/kg/d), whereas the low-volume group predominantly chose 0.2-0.3 mg/kg/d. While 44.9% preferred once-daily dosing, monitoring strategies varied. Primary discontinuation criteria included negative thyroid-stimulating hormone receptor antibodies, treatment duration, and reduction of thyroid volume. High-volume physicians favored longer treatment courses; the proportions of physicians assessing eligibility for discontinuation at < 2 years and ≥ 2 years were 7.2% and 87.1%, respectively, compared to 28.2% and 66.0% in the low-volume group.
conclusionHeterogeneity exists in childhood GD management in China. High-volume physicians tend to adopt proactive individualized dosing and longer treatment durations. High-quality evidence is needed to standardize clinical practice.
Indexed as
Identifiers
42430043What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.